Insight Guru Inc.

11/19/2026 | Press release | Distributed by Public on 11/19/2026 04:53

Eli Lilly Stopped Touting Dose Counts. Should You Worry

Today's big story: Could Anthropic Stock Fall 25%?

Eli Lilly (LLY) stock trades at 44.7 times earnings, against 21.5 for the S&P 500. Shareholders paying that price need to know what they are buying. And the company's priorities have shifted. On calls in February and August 2025, management emphasized how many doses of its weight-loss and diabetes drugs it could make. By its latest call, it stressed something else. So what does management talk up now instead?

At 44.7 times earnings, Eli Lilly shares look priced for years of strong growth. If that growth stumbles, a sharp drop is hard to sit through when the stock is a big part of your savings. When the market has fallen, the Trefis High Quality (HQ) Portfolio has lost about 81 cents for every $1 its benchmark lost, on average. See the HQ record.

Eli Lilly Now Talks Up Reaching More Patients

Management now talks up how many people it can reach, not how many doses it can make. On the fiscal Q4 2024 call, held in February 2025, management said it delivered on its target to make 1.5 times the salable doses. Six months later, on the fiscal Q2 2025 call, it reported more than 1.6 times the salable doses of these drugs. Those multiples backed its claim of a stronger supply position.

On the fiscal Q3 2026 call, held on October 29, 2026, management emphasized access instead. Through the Medicare GLP-1 bridge program, Eli Lilly expanded access to its obesity drugs for about 20 million US seniors. More than half a million people have filled a prescription for a Lilly medicine through it since July 1. Management also said Eli Lilly is still scratching the surface of the patients it can reach, reaching only about 1 in 10 in the US.

Management still talks about its factories, but now as building for future growth. The company broke ground on two new plants in the quarter, including a $6.5 billion site in Houston. Management no longer emphasizes the dose count.

How Big Are Mounjaro And Zepbound For Eli Lilly?

Management reported that Mounjaro and Zepbound generated more than $16 billion of revenue in fiscal Q3 2026. That figure accounts for roughly two-thirds of the company's $24.4 billion in total revenue for the quarter. The two treatments also delivered $6 billion of growth from a year earlier, out of nearly $7 billion in growth for the whole company.

The patients behind that growth are who management talks about now. In the US, use of this drug class for obesity grew 82% in the quarter. About 6 in 10 of those prescriptions were for a Lilly medicine. Revenue from Eli Lilly's key oncology, immunology and neuroscience drugs also doubled. But those drugs added far less than the two weight-loss and diabetes drugs.

Is Eli Lilly Trading Lower Prices For More Patients?

Yes, and so far the trade has worked. Eli Lilly's US revenue rose 34% in fiscal Q3 2026, mainly because the company sold more Zepbound and Mounjaro. Excluding a favorable change to its rebate estimates, its US price fell 10% during the same quarter. More volume more than offset those lower prices, offering a reassuring sign for shareholders.

The risk is that prices keep sliding. Management expects most of its 2027 access gains to come from Medicare and Medicaid. Those patients bring a lower net price per prescription. So Lilly's average price can fall because of who pays, even if it does not cut its prices. Eli Lilly still expects volume growth to more than offset lower prices, as in past years.

Revenue in 2027 also starts from a higher bar. About $2 billion of 2026 revenue stemmed from one-time items, mostly milestone payments and changes in rebate estimates, which management does not expect to recur. That slice represents about 2% of the $91 billion to $92 billion the company now expects for 2026.

For now, the shift in emphasis is reassuring. Eli Lilly no longer needs to prove it can make enough doses, and it is selling far more of them. The drugmaker is expected to report in February 2027, and those results will show how far its US price fell against the growth in volume.

When a single stock grows into a big part of your savings, one quarter of lower US prices can move a lot of your money at once. It helps to decide ahead of time how you would cut back.

Too Much Riding On One Stock?

If Eli Lilly is a big part of your wealth, so are its risk and its tax bill. What's your exit plan? Our partner advisory firm offers a free 30-minute strategy review covering a floor under losses and a lower-tax way out.

Map My Exit Options

Spot an error or want more like this? Tell us in 10 seconds.

Insight Guru Inc. published this content on November 19, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 19, 2026 at 10:53 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]